Document is current

Article History

Received: 18 February 2022

Accepted: 16 May 2022

First Online: 3 June 2022

Declarations

:

: M.J. has given lectures, received honoraria, participated in conferences and advisory boards sponsored by pharmaceutical companies including Amgen, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Novartis and Servier. A.J. has served as a consultant and is on Speakers Bureaus for AstraZeneca, Boehringer Ingelheim, Eli Lilly, MerckSharp & Dohme (MSD), Novo Nordisk, Medtronic and Sanofi. None of the above had any role in this article, which has been written independently, without any financial or professional help, and reflects only the authors' opinion, without any role of the industry. T.B. is supported in part by the Slovenian Research Agency grant # P3-0343. No potential conflicts of interest relevant to this article were reported.

: Our study has been reviewed by the national ethics committee and has been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki.

: All persons gave their informed consent prior to their inclusion in the study.

Free to read: This content has been made available to all.